Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

ZTS Dividends

Zoetis Inc. (ZTS) pays $2.06 in dividends per share, with a current dividend yield of 2.53%. The company has dividend history for 12 consecutive years.

ZTS Dividend Summary

Consecutive Years

12

Next Ex-Dividend Date

Jul 20, 2026

Next Payment Date

Sep 1, 2026

ZTS Dividends per Share (Nominal History)

View full nominal table list

This step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency.

ZTS Dividends CAGR Chart

Zoetis Inc. (ZTS)

Annual Dividend History

YearDividend/ShareYoY Growth
2026(YTD)$1.59
2025$2.00+15.74%
2024$1.73+15.20%
2023$1.50+15.38%
2022$1.30+30.00%
2021$1.00+25.00%
2020$0.80+21.95%
2019$0.66+30.16%
2018$0.50+20.00%
2017$0.42+10.53%
2016$0.38+14.46%
2015$0.33+15.28%
2014$0.29N/A
2013$0.20N/A

Quarterly Dividend History

QuarterDividend/ShareYoY Growth
Q3 2026$0.53+6.00%
Q2 2026$0.53+6.00%
Q1 2026$0.53+6.00%
Q4 2025$0.50+15.74%
Q3 2025$0.50+15.74%
Q2 2025$0.50+15.74%
Q1 2025$0.50+15.74%
Q4 2024$0.43+15.20%
Q3 2024$0.43+15.20%
Q2 2024$0.43+15.20%
Q1 2024$0.43+15.20%
Q4 2023$0.38+15.38%
Q3 2023$0.38+15.38%
Q2 2023$0.38+15.38%
Q1 2023$0.38+15.38%
Q4 2022$0.33+30.00%
Q3 2022$0.33+30.00%
Q2 2022$0.33+30.00%
Q1 2022$0.33+30.00%
Q4 2021$0.25+25.00%
Q3 2021$0.25+25.00%
Q2 2021$0.25+25.00%
Q1 2021$0.25+25.00%
Q4 2020$0.20+21.95%

Dividend Yield Metrics

Current Yield
2.53%
Average Yield (TTM)
2.53%
Average Yield (3Y)
2.14%
Forward Yield on Cost (3Y)
5.05%
Forward Yield on Cost (5Y)
8.02%
Forward Yield on Cost (10Y)
25.46%

Payout Ratio Analysis

Payout Ratio (Current)
34.16%
FCF Payout Ratio
42.77%
Payout Ratio (3Y Avg)
31.43%
Payout Ratio (5Y Avg)
29.28%
FCF Payout (3Y Avg)
38.56%
FCF Payout (5Y Avg)
37.79%

Dividend Coverage

Payout Ratio
34.2%
Dividends / net income
FCF Payout Ratio
42.8%
Dividends / free cash flow
Consecutive Years
12 years
Years with regular dividend payments
5Y Dividend Growth
20.1%
Compound annual dividend growth

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck